Christopher B. Nelson ^1*, Maureen Birmingham ², Alejandro Costa ³, Joelle Daviaud ³, William Perea ³, Marie-Paule Kieny ³, Daniel Tarantola ⁴

¹ Merck Vaccine Division (MVD), Merck & Co.
² WHO Thailand
³ WHO Geneva
⁴ formerly WHO Geneva

^* To whom correspondence should be addressed. E-mail: christopher_nelson{at}merck.com.

	Abstract

With the emergence of epidemic Neisseria meningitidis W135 meningitis in Burkina Faso during early 2002, the public health community was faced with the challenge of providing access to an appropriate and affordable vaccine in time for the upcoming 2003 epidemic season.

Recognizing the implications of the emergent threat, the World Health Organization developed a strategy, established a public-private partnership to provide the needed vaccine, and then ensured that a stockpile was available for future use.

The trivalent N meningitidis ACW135 polysaccharide vaccine that resulted is now one of the primary tools for epidemic response in African meningitis belt countries. It will remain so for the foreseeable future and until appropriate and affordable conjugate vaccines become part of national immunization programs in the region.

Key Words: Global Health, Immunization/Vaccines, Infections, Prevention, Surveillance